Literature DB >> 33798034

It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.

Brendan Saloner1, Barbara Andraka Christou2,3, Adam J Gordon4,5,6, Bradley D Stein7.   

Abstract

Buprenorphine is one of the gold standard medication treatments for opioid use disorder (OUD), with proven effectiveness in preventing overdose, increasing abstinence, and improving quality of life. In the United States, buprenorphine can be legally prescribed and administered in office-based settings from clinicians who are specially credentialed to provide that care under the X-waiver. We believe the X-waiver will ultimately be repealed, but there is a need for a variety of strategies to create a new treatment system after the X-waiver. Building a new tier of treatment capacity will require educational outreach, systems strategies, and enhanced payments.

Entities:  

Keywords:  Buprenorphine; DATA 2000; access to care; policy; quality of care

Mesh:

Substances:

Year:  2021        PMID: 33798034      PMCID: PMC8667660          DOI: 10.1080/08897077.2021.1903659

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  40 in total

1.  Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration.

Authors:  Adam J Gordon; Joseph Liberto; Stephanie Granda; Sara Salmon-Cox; Tykia Andree; Laura McNicholas
Journal:  Am J Addict       Date:  2008 Nov-Dec

2.  Geographic location of buprenorphine-waivered physicians and integration with health systems.

Authors:  Brendan Saloner; LeeKai Lin; Kosali Simon
Journal:  J Subst Abuse Treat       Date:  2020-05-12

3.  The Surgeon General's Facing Addiction report: An historic document for health care.

Authors:  Sharon Levy; J Paul Seale; Victoria A Osborne; Kevin L Kraemer; Daniel P Alford; Jeffrey Baxter; Deborah S Finnell; Hillary Kunins; Alexander Y Walley; David C Lewis; Doreen MacLane-Baeder; Adam J Gordon
Journal:  Subst Abus       Date:  2017 Apr-Jun       Impact factor: 3.716

4.  Medication-assisted therapies--tackling the opioid-overdose epidemic.

Authors:  Nora D Volkow; Thomas R Frieden; Pamela S Hyde; Stephen S Cha
Journal:  N Engl J Med       Date:  2014-04-23       Impact factor: 91.245

5.  Interest in prescribing buprenorphine among resident and attending physicians at an urban teaching clinic.

Authors:  Jocelyn R James; Leah M Gordon; Jared W Klein; Joseph O Merrill; Judith I Tsui
Journal:  Subst Abus       Date:  2018-04-26       Impact factor: 3.716

6.  Improved quality of life, clinical, and psychosocial outcomes among heroin-dependent patients on ambulatory buprenorphine maintenance.

Authors:  Alexander M Ponizovsky; Anatoly Margolis; Ludmila Heled; Paula Rosca; Irena Radomislensky; Alexander Grinshpoon
Journal:  Subst Use Misuse       Date:  2010       Impact factor: 2.164

7.  Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.

Authors:  Bradley D Stein; Rosalie Liccardo Pacula; Adam J Gordon; Rachel M Burns; Douglas L Leslie; Mark J Sorbero; Sebastian Bauhoff; Todd W Mandell; Andrew W Dick
Journal:  Milbank Q       Date:  2015-09       Impact factor: 4.911

8.  Medicare payment for cognitive vs procedural care: minding the gap.

Authors:  Christine A Sinsky; David C Dugdale
Journal:  JAMA Intern Med       Date:  2013-10-14       Impact factor: 21.873

9.  No end to the crisis without an end to the waiver.

Authors:  Joseph W Frank; Sarah E Wakeman; Adam J Gordon
Journal:  Subst Abus       Date:  2018       Impact factor: 3.716

10.  Monthly Patient Volumes of Buprenorphine-Waivered Clinicians in the US.

Authors:  Alexandra Duncan; Jared Anderman; Travis Deseran; Ian Reynolds; Bradley D Stein
Journal:  JAMA Netw Open       Date:  2020-08-03
View more
  8 in total

1.  Don't "Waive" Goodbye to Education for Opioid Use Disorder.

Authors:  Richard Bottner; Jeffrey Bratberg; Marlene Martin; Melissa B Weimer; Ayana Jordan; Matthew Tierney
Journal:  NAM Perspect       Date:  2021-10-04

2.  Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020.

Authors:  Bradley D Stein; Brendan Saloner; Rose Kerber; Mark Sorbero; Adam J Gordon
Journal:  Ann Emerg Med       Date:  2022-03-16       Impact factor: 6.762

3.  Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories.

Authors:  Irineo Cabreros; Beth Ann Griffin; Brendan Saloner; Adam J Gordon; Rose Kerber; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

4.  How Physician Workforce Shortages Are Hampering the Response to the Opioid Crisis.

Authors:  Jennifer McNeely; Daniel Schatz; Mark Olfson; Noa Appleton; Arthur Robin Williams
Journal:  Psychiatr Serv       Date:  2021-09-15       Impact factor: 4.157

5.  Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing.

Authors:  Barbara Andraka-Christou; Adam J Gordon; Joanne Spetz; Rachel Totaram; Matthew Golan; Olivia Randall-Kosich; Jordan Harrison; Spencer Calder; Stefan G Kertesz; Bradley D Stein
Journal:  J Subst Abuse Treat       Date:  2022-01-10

6.  Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.

Authors:  Susan L Calcaterra; Steve Lockhart; Catherine Callister; Kaitlyn Hoover; Ingrid A Binswanger
Journal:  J Gen Intern Med       Date:  2022-01-03       Impact factor: 6.473

7.  Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities.

Authors:  Hildi J Hagedorn; Allison M Gustavson; Princess E Ackland; Ann Bangerter; Mark Bounthavong; Barbara Clothier; Alex H S Harris; Marie E Kenny; Siamak Noorbaloochi; Hope A Salameh; Adam J Gordon
Journal:  J Gen Intern Med       Date:  2022-01-03       Impact factor: 6.473

8.  Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.

Authors:  Barbara Andraka-Christou; Cory Page; Victoria Schoebel; Jessica Buche; Rebecca L Haffajee
Journal:  Addict Sci Clin Pract       Date:  2022-08-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.